383 related articles for article (PubMed ID: 21126615)
41. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
[TBL] [Abstract][Full Text] [Related]
42. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics.
Longo-Mbenza B; Nkondi Nsenga J; Vangu Ngoma D
Int J Cardiol; 2007 Oct; 121(3):229-38. PubMed ID: 17368586
[TBL] [Abstract][Full Text] [Related]
43. Effects of obesity surgery on the metabolic syndrome.
Lee WJ; Huang MT; Wang W; Lin CM; Chen TC; Lai IR
Arch Surg; 2004 Oct; 139(10):1088-92. PubMed ID: 15492149
[TBL] [Abstract][Full Text] [Related]
44. Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
Haim M; Benderly M; Boyko V; Goldenberg I; Tanne D; Battler A; Goldbourt U; Behar S;
Coron Artery Dis; 2006 Aug; 17(5):455-61. PubMed ID: 16845254
[TBL] [Abstract][Full Text] [Related]
45. Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome.
Espinola-Klein C; Rupprecht HJ; Bickel C; Lackner K; Genth-Zotz S; Post F; Munzel T; Blankenberg S;
Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):278-84. PubMed ID: 18525381
[TBL] [Abstract][Full Text] [Related]
46. Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
Acharjee S; Qin J; Murphy SA; McCabe C; Cannon CP
Am J Cardiol; 2010 Mar; 105(5):619-23. PubMed ID: 20185006
[TBL] [Abstract][Full Text] [Related]
47. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
[TBL] [Abstract][Full Text] [Related]
48. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
Goldbourt U; Behar S; Reicher-Reiss H; Agmon J; Kaplinsky E; Graff E; Kishon Y; Caspi A; Weisbort J; Mandelzweig L
Am J Cardiol; 1993 Apr; 71(11):909-15. PubMed ID: 8465780
[TBL] [Abstract][Full Text] [Related]
49. Clinical impact of metabolic syndrome and its additive effect with smoking on subsequent cardiac events after acute myocardial infarction.
Nakatani D; Sakata Y; Sato H; Mizuno H; Shimizu M; Suna S; Ito H; Koretsune Y; Hirayama A; Hori M;
Am J Cardiol; 2007 Apr; 99(7):885-9. PubMed ID: 17398177
[TBL] [Abstract][Full Text] [Related]
50. Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database.
Rho YH; Woo JH; Choi SJ; Lee YH; Ji JD; Song GG
Metabolism; 2008 Jan; 57(1):71-6. PubMed ID: 18078861
[TBL] [Abstract][Full Text] [Related]
51. Association of uric acid with risk factors for chronic kidney disease and metabolic syndrome in patients with essential hypertension.
Seki S; Tsutsui K; Fujii T; Yamazaki K; Anzawa R; Yoshimura M
Clin Exp Hypertens; 2010; 32(5):270-7. PubMed ID: 20662727
[TBL] [Abstract][Full Text] [Related]
52. J-shaped mortality relationship for uric acid in CKD.
Suliman ME; Johnson RJ; García-López E; Qureshi AR; Molinaei H; Carrero JJ; Heimbürger O; Bárány P; Axelsson J; Lindholm B; Stenvinkel P
Am J Kidney Dis; 2006 Nov; 48(5):761-71. PubMed ID: 17059995
[TBL] [Abstract][Full Text] [Related]
53. Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease.
Haim M; Tanne D; Goldbourt U; Doolman R; Boyko V; Brunner D; Sela BA; Behar S
Cardiology; 2007; 107(1):52-6. PubMed ID: 16763372
[TBL] [Abstract][Full Text] [Related]
54. Poor functional status based on the New York Heart Association classification exposes the coronary patient to an elevated risk of ischemic stroke.
Koren-Morag N; Goldbourt U; Tanne D
Am Heart J; 2008 Mar; 155(3):515-20. PubMed ID: 18294489
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of metabolic syndrome in heart transplant patients: role of previous cardiopathy and years since the procedure--the TRACA study.
Cordero Fort A; Gavira JJ; Alegría-Barrero E; Castaño S; Martín A; Ubilla M; Mastrobuoni S; Alegría Ezquerra E; Herreros J; Rábago G
J Heart Lung Transplant; 2006 Oct; 25(10):1192-8. PubMed ID: 17045931
[TBL] [Abstract][Full Text] [Related]
56. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease.
Toprak O; Cirit M; Esi E; Postaci N; Yesil M; Bayata S
Catheter Cardiovasc Interv; 2006 Feb; 67(2):227-35. PubMed ID: 16400673
[TBL] [Abstract][Full Text] [Related]
57. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan.
Wang S; Shu Z; Tao Q; Yu C; Zhan S; Li L
Nephrology (Carlton); 2011 Nov; 16(8):767-76. PubMed ID: 21854506
[TBL] [Abstract][Full Text] [Related]
58. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
Yoshino G; Hirano T; Kazumi T
Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
[No Abstract] [Full Text] [Related]
59. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A
Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517
[TBL] [Abstract][Full Text] [Related]
60. Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome.
Klempfner R; Goldenberg I; Fisman EZ; Matetzky S; Amit U; Shemesh J; Tenenbaum A
Am J Cardiol; 2014 Jan; 113(1):12-6. PubMed ID: 24157192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
